University of Illinois at Chicago
Announcement of an Exempt Purchase
Vendor: CuraScript, Lake Mary, FL
Amount: An estimated $4,750,000
An estimated start date of 5/1/2020 through 4/30/2025
The University award process may be delayed up to thirty days as this award goes through a state approval process.
First published Wednesday, April 29, 2020
The University awarded a contract for Spinraza.
Spinraza is indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients. SMA is a rare neuromuscular disease and leading genetic cause of infant death or loss of motor function.
This purchase is exempt from the usual selection processes of the Procurement Code because the procurement expenditure is for medical supplies or medical services necessary for the delivery of care and treatment at medical, dental, or veterinary teaching facilities utilized by SIU or U of I (30 ILCS 500 / 1-13(b-5)) If the University of Illinois Hospital (UIH) does not have this therapy available to our neurologists, they will need to refer patients to other hospitals offering this therapy, resulting in a loss of revenue to UIH.
For instructions on how to obtain a comprehensive purchase description, disclosure or contract forms, contact:
The State of Illinois has a policy to encourage prospective vendors to hire
qualified veterans, minorities, females, persons with disabilities and ex-offenders.